These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 30365473)

  • 21. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.
    Pollom EL; Bui TT; Chang AL; Colevas AD; Hara WY
    JAMA Dermatol; 2015 Sep; 151(9):998-1001. PubMed ID: 25874733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant Vismodegib and Mohs Micrographic Surgery for Locally Advanced Periocular Basal Cell Carcinoma.
    González AR; Etchichury D; Gil ME; Del Aguila R
    Ophthalmic Plast Reconstr Surg; 2019; 35(1):56-61. PubMed ID: 30444747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of margin positive basal cell carcinoma with vismodegib: case report and consideration of treatment options and their implications.
    Bayers S; Kapp DL; Beer KR; Slavin B
    J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s147-50. PubMed ID: 24085060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry.
    Sekulic A; Yoo S; Kudchadkar R; Guillen J; Rogers G; Chang ALS; Guenthner S; Raskin B; Dawson K; Mun Y; Chu L; McKenna E; Lacouture M
    PLoS One; 2022; 17(1):e0262151. PubMed ID: 35030185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
    Lyseng-Williamson KA; Keating GM
    Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas.
    Sobanko JF; Okman J; Miller C
    J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s154-5. PubMed ID: 24085062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib.
    Bhutani T; Abrouk M; Sima CS; Sadetsky N; Hou J; Caro I; Chren MM; Arron ST
    J Am Acad Dermatol; 2017 Oct; 77(4):713-718. PubMed ID: 28780365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Periocular Basal Cell Carcinoma Predictors for Recurrence and Infiltration of the Orbit.
    Furdova A; Lukacko P
    J Craniofac Surg; 2017 Jan; 28(1):e84-e87. PubMed ID: 27906855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial.
    Kahana A; Unsworth SP; Andrews CA; Chan MP; Bresler SC; Bichakjian CK; Durham AB; Demirci H; Elner VM; Nelson CC; Kim DS; Joseph SS; Swiecicki PL; Worden FP
    Oncologist; 2021 Jul; 26(7):e1240-e1249. PubMed ID: 33988881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
    Cirrone F; Harris CS
    Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Vismodegib Therapy for Periocular Basal Cell Carcinoma].
    Keserü M; Green S; Dulz S
    Klin Monbl Augenheilkd; 2017 Jan; 234(1):64-69. PubMed ID: 28135752
    [No Abstract]   [Full Text] [Related]  

  • 33. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experience With Vismodegib in the Treatment of Advanced Basal Cell Carcinoma at a Cancer Center.
    Bernia E; Llombart B; Serra-Guillén C; Bancalari B; Nagore E; Requena C; Calomarde L; Diago A; Lavernia J; Traves V; Guillén C; Sanmartín O
    Actas Dermosifiliogr (Engl Ed); 2018 Nov; 109(9):813-820. PubMed ID: 30055751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma.
    Lavasidis G; Tzamalis A; Tsinopoulos I; Ziakas N
    Cancer Treat Res Commun; 2024; 39():100796. PubMed ID: 38367414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histologic Changes During Treatment With Vismodegib in Locally Advanced Basal Cell Carcinoma: A Series of 19 Cases.
    Bancalari B; Llombart B; Serra-Guillén C; Bernia E; Requena C; Nagore E; Traves V; Calomarde L; Diago A; Guillén C; Sanmartín O
    Am J Dermatopathol; 2019 Oct; 41(10):711-717. PubMed ID: 31436575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
    Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
    Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vismodegib: in locally advanced or metastatic basal cell carcinoma.
    Keating GM
    Drugs; 2012 Jul; 72(11):1535-41. PubMed ID: 22788238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant vismodegib in the management of locally advanced periocular basal cell carcinoma.
    Curragh DS; Huilgol SC; Selva D
    Eye (Lond); 2021 Oct; 35(10):2740-2745. PubMed ID: 33235336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vismodegib.
    Meiss F; Zeiser R
    Recent Results Cancer Res; 2014; 201():405-17. PubMed ID: 24756807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.